Friday, April 11, 2014

Global cancer immunotherapies market to reach $67.9 billion by 2018

Immunotherapy
for cancers utilizes biological response modifiers or vaccines to enhance the
endogenous immune response. Recent technological advances have made such
therapies more efficacious than the standard treatments of surgery, radiation,
and chemotherapy. Improving access to healthcare, increasing instances of
cancer, and the entry of new therapeutic drugs will drive tremendous growth in
this market for the foreseeable future.

BCC Research provides an in-depth analysis of the global market for cancer
immunotherapies through its report, Cancer Immunology and Oncolytic Virology: Technologies and Global Markets.
According to the report, this market was valued at $30.8 billion in 2012 and
nearly $34.3 billion for 2013. BCC Research expects the market to grow to $67.9
billion by 2018, and register a five-year compound annual growth rate of 14.7%
from 2013 to 2018.